Caterina MarchiÃ²

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8150464/publications.pdf

Version: 2024-02-01

161	7,095	53789	66906
papers	citations	45 h-index	78 g-index

162	162	162	10028
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. Cancer Research, 2010, 70, 2085-2094.	0.9	629
2	Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Research and Treatment, 2008, 111, 27-44.	2.5	287
3	Breast cancer precursors revisited: molecular features and progression pathways. Histopathology, 2010, 57, 171-192.	2.9	286
4	ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Annals of Oncology, 2019, 30, 1417-1427.	1.2	263
5	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics, 2014, 46, 1166-1169.	21.4	188
6	Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarrayâ€based CGH analysis. Journal of Pathology, 2009, 219, 16-24.	4.5	186
7	<scp>SF3B1</scp> mutations constitute a novel therapeutic target in breast cancer. Journal of Pathology, 2015, 235, 571-580.	4.5	167
8	Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond. Seminars in Cancer Biology, 2021, 72, 123-135.	9.6	162
9	Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers. Clinical Cancer Research, 2009, 15, 2711-2722.	7.0	152
10	PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas. Clinical Cancer Research, 2009, 15, 2269-2280.	7.0	147
11	Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intraâ€tumour genetic heterogeneity and clonal selection. Journal of Pathology, 2012, 227, 42-52.	4.5	138
12	Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. Journal of Pathology, 2008, 215, 398-410.	4.5	137
13	Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Laboratory Investigation, 2008, 88, 491-503.	3.7	130
14	Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. Npj Breast Cancer, 2016, 2, 16036.	5.2	127
15	Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr) Tj ETQq1 1 0.784314 rgBT /Ove	2.0	124
16	Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Seminars in Diagnostic Pathology, 2010, 27, 69-76.	1.5	108
17	Classification of pulmonary neuroendocrine tumors: new insights. Translational Lung Cancer Research, 2017, 6, 513-529.	2.8	104
18	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102

#	Article	IF	Citations
19	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. Journal of Clinical Pathology, 2007, 61, 327-332.	2.0	101
20	Salivary duct carcinomas can be classified into luminal androgen receptorâ€positive, HER2 and basalâ€like phenotypes*. Histopathology, 2012, 61, 629-643.	2.9	93
21	Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. Journal of Pathology, 2014, 232, 553-565.	4.5	88
22	Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6â€˜split apartâ€™ probes. Histopathology, 2008, 52, 840-846.	2.9	80
23	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. Genes Chromosomes and Cancer, 2009, 48, 351-365.	2.8	80
24	MED12 somatic mutations in fibroadenomas and phyllodes tumours of the breast. Histopathology, 2015, 67, 719-729.	2.9	78
25	ESR1 gene amplification in breast cancer: a common phenomenon?. Nature Genetics, 2008, 40, 809-810.	21.4	75
26	Mixed micropapillaryâ€“ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. Journal of Pathology, 2009, 218, 301-315.	4.5	73
27	Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocrine-Related Cancer, 2011, 18, 565-577.	3.1	73
28	Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues. Frontiers in Oncology, 2013, 3, 129.	2.8	73
29	The genomic profile of HER2 â€amplified breast cancers: the influence of ER status. Journal of Pathology, 2008, 216, 399-407.	4.5	72
30	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Frontiers in Oncology, 2021, 11, 644737.	2.8	70
31	Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2Î± Scaffolding Function. Cancer Cell, 2017, 32, 444-459.e7.	16.8	69
32	The Genomic Landscape of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 737-741.	6.3	68
33	Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 288-296.	2.8	67
34	Pleomorphism of the nuclear envelope in breast cancer: a new approach to an old problem. Journal of Cellular and Molecular Medicine, 2008, 12, 209-218.	3.6	67
35	Basic principles of biobanking: from biological samples to precision medicine for patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 233-246.	2.8	67
36	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. Pathobiology, 2018, 85, 23-34.	3.8	65

#	Article	IF	Citations
37	Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 713-720.	2.8	64
38	Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Modern Pathology, 2018, 31, 68-82.	5.5	58
39	Nestin is expressed in basal-like and triple negative breast cancers. Journal of Clinical Pathology, 2008, 61, 1045-1050.	2.0	55
40	CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Research and Treatment, 2010, 120, 95-109.	2.5	53
41	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesisâ€generating study. Journal of Pathology, 2015, 237, 166-178.	4.5	53
42	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cellâ€“Intrinsic Transcriptional MSI Traits. Cancer Research, 2019, 79, 5884-5896.	0.9	53
43	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology, 2012, 60, E115-30.	2.9	52
44	The genetic landscape of breast carcinomas with neuroendocrine differentiation. Journal of Pathology, 2017, 241, 405-419.	4.5	52
45	BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical Cancer Research, 2016, 22, 4923-4933.	7.0	50
46	The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. Pathobiology, 2020, 87, 125-142.	3.8	49
47	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. Modern Pathology, 2017, 30, 69-84.	5.5	48
48	Hereditary breast cancer: from molecular pathology to tailored therapies. Journal of Clinical Pathology, 2008, 61, 1073-1082.	2.0	45
49	The role of molecular analysis in breast cancer. Pathology, 2009, 41, 77-88.	0.6	44
50	Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast. Human Pathology, 2015, 46, 1350-1359.	2.0	44
51	Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors. Drug Delivery, 2017, 24, 670-680.	5.7	41
52	The expression of Wilmsâ€™ tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. Histopathology, 2007, 51, 824-828.	2.9	39
53	Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers. Cell Death and Differentiation, 2019, 26, 2223-2236.	11.2	39
54	miR-221/222 control luminal breast cancer tumor progression by regulating different targets. Cell Cycle, 2014, 13, 1811-1826.	2.6	38

#	Article	IF	Citations
55	PAX8â€“GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. Modern Pathology, 2019, 32, 1734-1743.	5.5	38
56	Gene Status in HER2 Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based Method. Oncologist, 2014, 19, 1118-1126.	3.7	37
57	Molecular alterations of neuroendocrine tumours of the lung. Histopathology, 2018, 72, 142-152.	2.9	37
58	Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box. BMC Medicine, 2011, 9, 41.	5.5	35
59	Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. Molecular Cytogenetics, 2014, 7, 8.	0.9	35
60	Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. Cancers, 2021, 13, 3695.	3.7	35
61	Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Research and Treatment, 2014, 148, 511-523.	2.5	34
62	High rate of <scp>PIK</scp>3<scp>CA</scp> mutations but no <scp>TP</scp>53 mutations in lowâ€grade adenosquamous carcinoma of the breast. Histopathology, 2018, 73, 273-283.	2.9	33
63	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Journal of Experimental and Clinical Cancer Research, 2020, 39, 279.	8.6	32
64	The Pathologic Complete Response Open Question in Primary Therapy. Journal of the National Cancer Institute Monographs, 2011, 2011, 86-90.	2.1	30
65	Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. Laboratory Investigation, 2015, 95, 561-571.	3.7	30
66	Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor. Npj Breast Cancer, 2016, 2, 16035.	5.2	28
67	A Collection of Primary Tissue Cultures of Tumors from Vacuum Packed and Cooled Surgical Specimens: A Feasibility Study. PLoS ONE, 2013, 8, e75193.	2.5	28
68	Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples. PLoS ONE, 2017, 12, e0182965.	2.5	27
69	RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples. Communications Biology, 2018, 1, 209.	4.4	26
70	ESR1 mutations in metastatic lobular breast cancer patients. Npj Breast Cancer, 2019, 5, 9.	5.2	26
71	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open, 2022, 7, 100459.	4.5	26
72	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology, 2020, 33, 354-366.	5.5	25

#	Article	IF	Citations
73	AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells. Cells, 2020, 9, 247.	4.1	25
74	â€œTo Be or Not to Be in a Good Shapeâ€• Diagnostic and Clinical Value of Nuclear Shape Irregularities in Thyroid and Breast Cancer. Advances in Experimental Medicine and Biology, 2014, 773, 101-121.	1.6	25
75	Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study. Modern Pathology, 2010, 23, 260-269.	5.5	24
76	Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization. Oncotarget, 2017, 8, 18680-18698.	1.8	24
77	Tissue arrays as fiducial markers for section alignment in 3-D reconstruction technology. Journal of Cellular and Molecular Medicine, 2005, 9, 438-445.	3.6	23
78	Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. Oncogene, 2014, 33, 619-631.	5.9	23
79	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq1 1 0.784314 rgBT /Ov 1137.	3.7	22
80	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research, 2020, 26, 6254-6265.	7.0	22
81	Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer. Frontiers in Oncology, 2020, 10, 173.	2.8	22
82	Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. BMC Cancer, 2014, 14, 922.	2.6	21
83	The expression of LINE1â€MET chimeric transcript identifies a subgroup of aggressive breast cancers. International Journal of Cancer, 2018, 143, 2838-2848.	5.1	21
84	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	4.6	21
85	A new vision of tubular and tubulo-lobular carcinomas of the breast, as revealed by 3-D modelling. Histopathology, 2006, 48, 556-562.	2.9	20
86	The Dilemma of HER2 Double-equivocal Breast Carcinomas. American Journal of Surgical Pathology, 2018, 42, 1190-1200.	3.7	20
87	Definition of High-Risk Early Hormone-Positive HER2â^'Negative Breast Cancer: A Consensus Review. Cancers, 2022, 14, 1898.	3.7	20
88	ESR1 amplification in endometrial carcinomas: hope or hyperbole?. Journal of Pathology, 2008, 216, 271-274.	4.5	18
89	Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives. Pathobiology, 2022, 89, 278-296.	3.8	18
90	Search for Neuro-Endocrine Markers (Chromogranin A, Synaptophysin and VGF) in Breast Cancers. An integrated Approach Using Immunohistochemistry and Gene Expression Profiling. Endocrine Pathology, 2014, 25, 219-228.	9.0	17

#	Article	IF	Citations
91	Spontaneous and pronaseâ€induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. Journal of Pathology, 2013, 229, 390-399.	4.5	16
92	High-Throughput Molecular Analysis from Leftover of Fine Needle Aspiration Cytology of Mammographically Detected Breast Cancer. Translational Oncology, 2012, 5, 180-IN5.	3.7	15
93	PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas. Gynecologic Oncology, 2015, 137, 321-328.	1.4	15
94	The Perfect Pathology Report After Neoadjuvant Therapy. Journal of the National Cancer Institute Monographs, 2015, 2015, 47-50.	2.1	15
95	Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study. Histopathology, 2019, 75, 312-319.	2.9	15
96	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	5.5	14
97	Molecular diagnosis in breast cancer. Diagnostic Histopathology, 2008, 14, 202-213.	0.4	13
98	Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. Neuro-Oncology, 2017, 19, now244.	1.2	13
99	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. Pathologica, 2021, 113, 262-271.	3.4	13
100	Patients with advanced stage breast carcinoma immunoreactive to biotinylated HerceptinÂ® are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Annals of Oncology, 2007, 18, 1963-1968.	1.2	12
101	Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression. American Journal of Pathology, 2018, 188, 2378-2391.	3.8	12
102	CUTseq is a versatile method for preparing multiplexed DNA sequencing libraries from low-input samples. Nature Communications, 2019, 10, 4732.	12.8	12
103	Predictive Diagnostic Pathology in the Target Therapy Era in Breast Cancer. Current Drug Targets, 2016, 18, 4-12.	2.1	12
104	Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. Endocrine-Related Cancer, 2016, 23, 635-650.	3.1	11
105	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. Current Breast Cancer Reports, 2017, 9, 34-44.	1.0	11
106	Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast. Molecular Oncology, 2017, 11, 913-926.	4.6	11
107	Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 3126-3140.	7.0	11
108	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patientsÂundergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio â‰¥2.0, HER2) Tj ETQq0 0 0 rgBT /Overloc		

#	Article	IF	Citations
109	Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast, 2021, 59, 94-101.	2.2	11
110	Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors. Npj Precision Oncology, 2022, 6, 15.	5.4	11
111	Myxoid Renal Tumor With Myoepithelial Differentiation Mimicking a Salivary Gland Pleomorphic Adenoma: Description of a Case. American Journal of Surgical Pathology, 2007, 31, 632-636.	3.7	10
112	Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. Tumor Biology, 2017, 39, 101042831769431.	1.8	10
113	Tissues under-vacuum to overcome suboptimal preservation. New Biotechnology, 2019, 52, 104-109.	4.4	10
114	Oncogenic properties and signaling basis of the PAX8â€GLIS3 fusion gene. International Journal of Cancer, 2020, 147, 2253-2264.	5.1	10
115	Molecular Characterization of Prostate Cancers in the Precision Medicine Era. Cancers, 2021, 13, 4771.	3.7	10
116	The expression of GHRH and its receptors in breast carcinomas with apocrine differentiationâ€”further evidence of the presence of a GHRH pathway in these tumors. Human Pathology, 2017, 64, 164-170.	2.0	9
117	Incorporation of TILs in daily breast cancer care: how much evidence can we bear?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 147-162.	2.8	9
118	Chemotherapy with or without trastuzumab. Annals of Oncology, 2010, 21, vii112-vii119.	1.2	8
119	Wellâ€differentiated neuroendocrine tumour of the breast showing peculiar endovascular spread. Histopathology, 2014, 64, 597-600.	2.9	8
120	RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. European Journal of Cancer, 2016, 64, 149-158.	2.8	8
121	Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients. Cancers, 2021, 13, 3376.	3.7	8
122	Intra-Tumour Heterogeneity Is One of the Main Sources of Inter-Observer Variation in Scoring Stromal Tumour Infiltrating Lymphocytes in Triple Negative Breast Cancer. Cancers, 2021, 13, 4410.	3.7	8
123	Rediscovering Secondary Tumors of the Prostate in the Molecular Era. Advances in Anatomic Pathology, 2016, 23, 170-179.	4.3	7
124	Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene. British Journal of Cancer, 2017, 117, 358-366.	6.4	7
125	Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices. Expert Review of Molecular Diagnostics, 2018, 18, 467-475.	3.1	7
126	Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal. Breast, 2020, 53, 181-188.	2.2	7

#	Article	IF	Citations
127	HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast. Journal of Hematology and Oncology, 2021, 14, 143.	17.0	7
128	Traditional urinary cytology and tyrosinase RT-PCR in metastatic melanoma patients: correlation with clinical status. Journal of Clinical Pathology, 2007, 61, 179-183.	2.0	6
129	Smallâ€cell carcinoma of the breast with squamous differentiation. Histopathology, 2013, 63, 739-741.	2.9	6
130	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. Cancers, 2021, 13, 894.	3.7	6
131	Personalized therapeutic strategies in HER2-driven gastric cancer. Gastric Cancer, 2021, 24, 897-912.	5.3	6
132	Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. Tumori, 2022, 108, 196-203.	1.1	6
133	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. Journal of Clinical Pathology, 2020, , jclinpath-2020-207052.	2.0	5
134	Current Projects in Pre-analytics: Where to Go?. Recent Results in Cancer Research, 2015, 199, 65-70.	1.8	5
135	The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients. PLoS ONE, 2017, 12, e0182073.	2.5	5
136	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. Journal of Experimental and Clinical Cancer Research, 2017, 36, 143.	8.6	4
137	Molecular diagnosis in breast cancer. Diagnostic Histopathology, 2018, 24, 71-82.	0.4	4
138	Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. Cancers, 2019, 11, 454.	3.7	4
139	â€œGiants in a Microcosmâ€• International Journal of Surgical Pathology, 2015, 23, 654-655.	0.8	3
140	The Immune Landscape in Women Cancers. Cancer Treatment and Research, 2020, 180, 215-249.	0.5	3
141	â€œBorderlineâ€•epithelial lesions of the breast: what have we learned in the past three decades?. Pathologica, 2021, 113, 354-359.	3.4	3
142	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. Histopathology, 2017, 71, 480-487.	2.9	2
143	Nextâ€generation learning and training: The <scp>C</scp>yâ€<scp>TEST</scp> experience. Cancer Cytopathology, 2017, 125, 669-673.	2.4	2
144	CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoidsÂ- a short report. Cellular Oncology (Dordrecht), 2018, 41, 687-691.	4.4	2

#	Article	IF	Citations
145	HER2 in Breast Cancer. Encyclopedia of Pathology, 2019, , 1-11.	0.0	2
146	Pathology and Molecular Pathology of Breast Cancer. , 2017, , 173-231.		1
147	Microglandular Adenosis. Encyclopedia of Pathology, 2020, , 289-293.	0.0	1
148	Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer. JAMA Oncology, 2020, 6, 584.	7.1	0
149	Abstract 4829: Massively parallel RNA sequencing analysis of micropapillary carcinomas of the breast. , 2011, , .		0
150	Abstract P1-07-27: Neutrophil elastase modulates breast cancer progression by fostering collective cell detachment and tumor emboli dissemination. , 2015, , .		0
151	Abstract 4817: Microsatellite instability status in endometrioid endometrial carcinomas is associated with distinct types and patterns of PI3K pathway mutations. , 2015, , .		0
152	Abstract 3885: Mutational landscape and copy number alterations of mucinous breast carcinoma. , 2015, , .		0
153	Abstract A2-02: SF3B1 mutations constitute a novel therapeutic target in breast cancer. , 2015, , .		0
154	Abstract 91: The mutational landscape of mucinous carcinomas of the breast. , 2016, , .		0
155	Microglandular Adenosis. Encyclopedia of Pathology, 2019, , 1-5.	0.0	0
156	Abstract 261: L1-METtranscription silencing modulatesMETandEGFRgene and their protein expression and induces apoptosis and cell-death in different types of cancer cells. , 2019, , .		0
157	Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast.. Journal of Clinical Oncology, 2020, 38, e12570-e12570.	1.6	0
158	HER2 in Breast Cancer. Encyclopedia of Pathology, 2020, , 151-161.	0.0	0
159	Evoluzione dellâ€™istopatologia: da flatlandia a una visione a tre dimensioni. , 2007, , 255-261.		0
160	Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification. American Journal of Cancer Research, 2015, 5, 2212-21.	1.4	0
161	The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients. Cells, 2022, 11, 1944.	4.1	0